Net sales has been reported at Rs 90.04 crores for the year ended March 31, 2015
Hester Biosciences has posted FY 2014-15 results. The net profit for FY14-15 has been reported at Rs 14.58 crores as compared to Rs 10.08 crores for the previous corresponding period, thereby registering a growth of 45 per cent.
Net sales has been reported at Rs 90.04 crores for the year ended March 31, 2015 as compared to Rs 69.04 crores for the previous corresponding period, thereby registering a growth of 30 per cent. The net profit margin rose to 16.20 per cent in FY14-15 from 14.61 per cent in FY13-14. Earnings per share are at Rs 17.14 for the year ended March 31, 2015 as compared to Rs 11.86 for the year ended on March 31, 2014.
In line with the dividend payout policy of the company, the board of directors has recommended a dividend of 31 per cent, which is Rs 3.10 per equity share, subject to approval from the shareholders.
Rajiv Gandhi, Chief Executive Officer and Managing Director mentioned, “The overall performance of the company has been in line with the projections. Going further, the launch of large animal vaccines in March 2015, particularly of the PPR vaccine and the commencement of production in Nepal by September 2015 (a delay of two months because of the earthquake), would fuel the topline growth in the next financial year. PPR eradication programme has been embarked on by FAO of the UN. It has been estimated that the vaccination costs alone for the PPR eradication project over a 15-year period would be Rs 45,000 crores. The company’s endeavour to improve the bottom line continues.